Following a constructive meeting with Dr Satu Vainikka and other company members last Friday at Valirx in which the 2 primary elements of our open letter were re-iterated: namely management alignment with regards to their Valirx stock holdings and the corporate capital financing approach pursued by the company in recent years, I believe that going forward these will be addressed to all shareholders benefits.

That the company has potentially very valuable products with material market penetration opportunities has never been in question and post the meet we are more emboldened in our view of the unique asymmetric risk/reward opportunity presented at the current stock price.  We look forward to hoped for progress on the commercialisation front unfolding in the months ahead.

R Jennings

• ValiRx